Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia

被引:96
作者
Eriksson, Daniel [1 ]
Goldsmith, David [2 ]
Teitsson, Siguroli [1 ]
Jackson, James [3 ]
van Nooten, Floortje [4 ]
机构
[1] Quantify Res, Stockholm, Sweden
[2] Guys & St Thomas NHS Fdn Hosp, Renal Unit, London, England
[3] Adelphi Real World, Macclesfield, Cheshire, England
[4] Astellas Pharma, Leiden, Netherlands
关键词
Anaemia; Chronic kidney disease; EQ-5D; Fatigue; KDQOL-36; Quality of life; SF-12; Utility; CHRONIC KIDNEY-DISEASE; WORK PRODUCTIVITY; IMPAIRMENT; COUNTRIES; UTILITY; IMPACT; ALPHA;
D O I
10.1186/s12882-016-0312-9
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Deteriorating renal function in chronic kidney disease (CKD) patients is commonly associated with reduced haemoglobin levels, adding to the already considerable humanistic burden of CKD. This analysis evaluated the impact of anaemia on disease burden in patients with CKD stages 3-4, and in those on dialysis. Methods: This was a descriptive, cross-sectional analysis of European data from an Adelphi CKD Disease-Specific Programme. This programme collected data from patients and their treating nephrologists/endocrinologists; patient-and physician-reported data were matched for each patient. Health-related quality of life (HRQoL) data were obtained through patient completion of the EQ-5D, SF-12 and KDQOL-36. Additional information was obtained via physician reporting of patient symptoms, and patients' reports of impaired activity. Anaemia was defined by haemoglobin level and/or current use of erythropoiesis stimulating agents. Results: Significant, but modest Spearman's rank correlations were observed between haemoglobin levels and extent of HRQoL impairment, regardless of instrument used (range 0.19-0.23; all P-values < 0.0001). When stratified by anaemia status, impairment was consistently lower for anaemic than non-anaemic CKD patients across measurement scales (e.g. EQ-5D index value [standard deviation {SD}] 0.72 [0.31] vs 0.83 [0.23], respectively; P < 0. 0001). Physician-reported patient tiredness was associated with increased disease burden at all levels of CKD studied (total EQ-5D index value [SD] in patients reporting no tiredness vs tiredness 0.81 [0.26] vs 0.70 [0.30] respectively; P < 0.0001) with P < 0.0001 for no tiredness vs tiredness at all stages of CKD. The presence of anaemia was associated with impaired activity levels at CKD stages 3 (37.5 % vs 28.4 %, respectively; P = 0.0044) and 4 (48.1 % vs 39.9 %, respectively; P = 0.0292), and in patients on dialysis (52.0 % vs 45.0 %, respectively; P = 0.0732). Conclusions: The analysis found that CKD patients with anaemia typically had a lower HRQoL than those without anaemia. The impairment correlated with anaemia was more apparent in non-dialysis patients with CKD stages 3 or 4 than in those receiving dialysis. Coexisting CKD and anaemia may have an impact on patient HRQoL similar to other chronic conditions such as diabetes, epilepsy or certain forms of cancer.
引用
收藏
页数:10
相关论文
共 24 条
[1]   The relationship between EQ-5D, HAQ and pain in patients with rheumatoid arthritis [J].
Alava, Monica Hernandez ;
Wailoo, Allan ;
Wolfe, Fred ;
Michaud, Kaleb .
RHEUMATOLOGY, 2013, 52 (05) :944-950
[2]   Real-world physician and patient behaviour across countries: Disease-Specific Programmes - a means to understand [J].
Anderson, P. ;
Benford, M. ;
Harris, N. ;
Karavali, M. ;
Piercy, J. .
CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (11) :3063-3072
[3]   Association of anemia with worsened activities of daily living and health-related quality of life scores derived from the Minimum Data Set in long-term care residents [J].
Bailey, Robert A. ;
Reardon, Gregory ;
Wasserman, Michael R. ;
McKenzie, R. Scott ;
Hord, R. Steve .
HEALTH AND QUALITY OF LIFE OUTCOMES, 2012, 10
[4]  
Cheng Calvino Ka-Wing, 2004, Lab Hematol, V10, P42, DOI 10.1532/LH96.04010
[5]   Prevalence of Anemia in Patients with Type II Diabetes and Mild to Moderate Chronic Kidney Disease and the Impact of Anti-RAS Medications [J].
Dousdampanis, Periklis ;
Trigka, Konstantina ;
Fourtounas, Costas .
SAUDI JOURNAL OF KIDNEY DISEASES AND TRANSPLANTATION, 2014, 25 (03) :552-557
[6]   Normalization of hemoglobin level in patients with chronic kidney disease and anemia [J].
Drueke, Tilman B. ;
Locatelli, Francesco ;
Clyne, Naomi ;
Eckardt, Kai-Uwe ;
Macdougall, Iain C. ;
Tsakiris, Dimitrios ;
Burger, Hans-Ulrich ;
Scherhag, Armin .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (20) :2071-2084
[7]   Time to Reconsider Evidence for Anaemia Treatment (TREAT) = Essential Safety Arguments (ESA) [J].
Goldsmith, David ;
Covic, Adrian .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2010, 25 (06) :1734-1737
[8]   DEVELOPMENT OF THE KIDNEY-DISEASE QUALITY-OF-LIFE (KDQOL(TM)) INSTRUMENT [J].
HAYS, RD ;
KALLICH, JD ;
MAPES, DL ;
COONS, SJ ;
CARTER, WB .
QUALITY OF LIFE RESEARCH, 1994, 3 (05) :329-338
[9]   The impact of CKD identification in large countries: the burden of illness [J].
Jha, Vivekanand ;
Wang, Angela Yee-Moon ;
Wang, HaiYan .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 :32-38
[10]  
Levin A, 2013, KIDNEY INT SUPPL, V3, P5, DOI [10.1038/ki.2013.91, 10.1038/kisup.2012.77]